The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective-Reference-Cited by-同舟云学术

The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective

Published:2018-05-17 Issue:5 Volume:13 Page:e0197670
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

van Asten Freekje^ORCID,Michels Charlotte T. J.,Hoyng Carel B.,van der Wilt Gert Jan,Klevering B. Jeroen,Rovers Maroeska M.,Grutters Janneke P. C.

Funder

Radboud Institute for Health Sciences

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Why have UK doctors been deterred from prescribing Avastin?;D Cohen;BMJ,2015

2. National Institute for Health Care Excellence (NICE). Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, 2008.

3. National Institute for Health Care Excellence (NICE). Aflibercept solution for injection for treating wet age-related macular degeneration, 2013.

4. Office of Inspector General. Medicare Payments for Drugs Used to Treat Wet Age-Related Macular Degeneration. OEI-03-10-00360. Department of Health and Human Services, Washington DC, 2012.

5. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis;WL Wong;Lancet Glob Health,2014

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Formulation development of thermoresponsive quercetin nanoemulgels and in vitro investigation of their inhibitory activity on vascular endothelial growth factor-A inducing neovascularization from the retinal pigment epithelial cells;Journal of Drug Delivery Science and Technology;2024-10

2. Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis;Current Medical Research and Opinion;2024-06-12

3. Off-label use of intravitreal bevacizumab: A global conundrum;Indian Journal of Ophthalmology;2024-04-22

4. Fellow Eyes Conversion Rates in Patients With Unilateral Exudative Age-Related Macular Degeneration: An Academy IRIS ^® Registry Analysis;Ophthalmic Surgery, Lasers and Imaging Retina;2024-04

5. Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells;PLOS ONE;2024-03-27